Australian-based bio-separations company Memphasys has gained today on news it is joining forces with leading IVF specialists, Monash IVF Group for the commercial development of its proprietary sperm separation system.
The system, called Felix and developed in conjunction with world renowned fertility expert Prof John Aitken, provides a unique and critical advantage over current sperm processing methods by selecting the most viable, least DNA-damaged sperm for human IVF procedures.
Over the past six months, Monash IVF have been working with Memphasys in testing and providing feedback on the operation of the current Felix prototype device.
With the signing of this Collaborative Agreement, Monash IVF clinicians and researchers will now provide advice on the design and operation of the new Felix device to be marketed to IVF clinics globally.
ASX-listed Monash IVF operates within the field of fertility services – one of the largest providers of assisted reproductive services in Australia and Malaysia.
Initial sales of Felix systems anticipated for end CY 2019.
Memphasys is delighted to have Monash IVF as a collaborative partner, to provide vital clinical and regulatory input to assist in the commercial development of the Felix device,” Memphasys Executive Chairman Alison Coutts said.
Monash IVF Chief Research and Development Officer Professor Michelle Lane of said the company saw great potential in the Felix device to provide a new treatment paradigm for male infertility.
“We are keen to assist Memphasys to bring the device to commercial fruition,” she said.
Monash IVF will take equity in Memphasys for its services and have first rights for utilising the device in Monash IVF clinics for a 12-month period when it becomes commercially available.
Shares in Memphasys closed Tuesday 0.3c higher at 1.5c.